Adjuvant Sintilimab and Bevacizumab Biosimilar Treatment After Surgery for Ruptured Liver Cancer Hepatocellular Carcinoma
Led by Ruijin Hospital · Updated on 2026-03-27
35
Participants Needed
4
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with hepatocellular carcinoma HCC who have experienced spontaneous tumor rupture with hemorrhage. This condition has a high risk of death and recurrence after surgery, especially in Asian populations. The study evaluates the use of a combination of two drugs, sintilimab and a bevacizumab biosimilar, as additional treatment after surgical removal of the tumor. This is a Phase II, single-arm study aiming to find out if this treatment is tolerable and may improve outcomes for these high-risk patients.
Participants will receive sintilimab 200 mg and bevacizumab biosimilar 15 mgkg intravenously on day 1 every three weeks. Treatment will continue after surgery for up to three years. The study focuses on patients who have undergone complete tumor removal, have good liver function, and no remaining visible cancer. The combination therapy is given as an adjuvant treatment to potentially delay or prevent cancer recurrence.
During the study, participants will be monitored regularly for disease-free survival, overall survival, and any side effects using standard criteria. Imaging and laboratory tests will be done to check for liver cancer recurrence or spread within and outside the liver. The study will last up to three years, with ongoing assessments to track the timing and proportion of cancer recurrence or metastasis. Safety and tolerability of the treatment will also be closely observed throughout the study period.
CONDITIONS
Brief Title
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Research Team
Y
Yongjun Chen
F
Feng Ye
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients aged 18 to 75 years, male or female, who voluntarily provide written informed consent
Confirmed spontaneous tumor rupture with hemorrhage and postoperative pathological diagnosis of hepatocellular carcinoma
CNLC Stage I-II
Completed curative surgical resection with negative margins and complete response confirmed by imaging within 4-8 weeks after surgery
ECOG performance status 0 or 1
Child-Pugh class A with score 6 or less
Life expectancy of at least 12 months
Laboratory tests within 3 days prior to first dose meet specified blood counts, liver and kidney function criteria
For hepatitis B virus (HBV) infected patients, HBV DNA below 2000 IU/mL with antiviral treatment and continued therapy during study
Female patients of childbearing potential must have negative pregnancy test and agree to effective contraception, as must male patients with partners of childbearing potential
You will not qualify if you...
Diagnosis other than hepatocellular carcinoma, including cholangiocarcinoma or combined types
Intraoperative use of chemotherapeutic agents for lavage
Child-Pugh class B or C
ECOG performance status greater than 1
Presence of extrahepatic metastasis, residual disease, or recurrence on postoperative imaging
Prior systemic antitumor therapies or adjuvant transarterial chemoembolization after resection
Moderate or severe ascites requiring drainage or significant pleural/pericardial effusions
Current or history of interstitial lung disease or active pneumonia
Active autoimmune disease or history of autoimmune disease with recurrence potential, except well-controlled hypothyroidism and some mild conditions
Use of immunosuppressive agents or corticosteroids above specified doses within 2 weeks prior to treatment
History of recent gastrointestinal bleeding or high-risk varices without appropriate assessment
Known bleeding or clotting disorders or recent thrombotic events
Significant uncontrolled cardiac disease or hypertension
Major vascular disease or recent serious cardiovascular events
Severe wounds, ulcers, or unhealed fractures
Inability to absorb or swallow medication
Severe infection or fever within specified recent periods
Known immunodeficiency including HIV
Recent administration or anticipated need for live vaccines during study
Other conditions that may affect safety or study results as judged by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 3 years
Participants receive Sintilimab combined with bevacizumab biosimilar as adjuvant treatment after surgery.
Treatment cycles every 3 weeks with intravenous infusions
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Clinical Study of 68Ga-NYM207 PETCT Imaging to Detect Hepatocellular Carcinoma
Study of Personalized Neoantigen mRNA Therapy iNeo-Vac-R01 with PD-1 Inhibitor as Adjuvant Treatment After Liver Cancer Surgery
Study Comparing MRI and Ultrasound for Detecting Liver Cancer and Risk Factors in Adults with Liver Cirrhosis
Development and Validation of a Noninvasive Blood Test Using MicroRNA to Detect Multiple Gastrointestinal Cancers Early
Evaluating Safety, Tolerability, and Preliminary Effectiveness of Oral VMD-102 in Adults with Advanced Liver Cancer and Other Solid Tumors
Phase 1 Open-Label Study of CTX-10726 Safety and Tolerability in Patients with Advanced Cancers
Study of ST-01156, an Oral RBM39 Degrader, in Patients with Advanced Solid Tumors
Phase I Study Evaluating Safety and Dose Levels of CREPT-618 in Adults With Advanced Hepatocellular Carcinoma Who Have Failed Standard Treatment
Study of CBA-1205 Antibody for Advanced Solid Tumors, Liver Cancer, Melanoma, and Pediatric Cancers Evaluating Safety and Tolerability
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Adjuvant Sintilimab Plus Bevacizumab After Curative Resection of Spontaneously Ruptured Hepatocellular Carcinoma: Protocol for a Prospective, Exploratory, Single-Arm Study (CLEAR-2).